Air Methods Reports 3Q2009 Results and 4Q2...((Amounts in thousands) ...),Health

Date:11/5/2009

(Amounts in thousands) September 30, December 31, 2009 2008 ------------- ------------ ASSETS ------ Current assets: Cash and cash equivalents $23,181 13,147 Trade receivables, net 126,109 133,467 Other current assets 58,187 61,134 ------ ------ Total current assets 207,477 207,748 Net property and equipment 183,603 146,167 Other assets, net 38,338 41,009 ------ ------ Total assets $429,418 394,924 ======== ======= LIABILITIES AND STOCKHOLDERS' EQUITY ------------------------------------ Current liabilities: Notes payable related to assets held for sale $12,531 19,520 Current portion of indebtedness 15,330 15,638 Accounts payable, accrued expenses and other 64,152 56,628 ------ ------ Total current liabilities 92,013 91,786 Long-term indebtedness 88,429 85,858 Other non-current liabilities 56,776 56,816 ------ ------ Total liabilities 237,218 234,460 Total stockholders' equity 192,200 160,464 -------
'/>"/>

SOURCE Air Methods Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
2. Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder
3. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
4. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
5. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs